On Wednesday, AstraZeneca revealed that its experimental lung drug PT003 against chronic lung disease had been successful in the last two final-stage Phase III trials. This is such a great day for the company.
The drug, which AstraZeneca acquired after buying Pearl Therapeutics two years ago, combines a long-acting beta-2 agonist (LABA) and a long-acting muscarine antagonist (LAMA). AstraZeneca plans to file PT003 for approval commencing in 2015.
Rival firms also have LAMA/LABA drugs that are more advanced than PT003, but AstraZeneca’s drug is administered with a pressurized meter-dose inhaler instead of a dry-powder inhaler, which may suit elderly patients in particular.